The global cold plasma market size was valued at USD 55.84 million in 2017 and is expected to register a CAGR of 15.2% over the forecast period. Demand for cold plasma is increasing due to its extensive usage in medical treatment. In addition, rising cases of Hospital-Acquired Infections (HAIs), due to the lack of sanitation and precaution, are projected to boost the product demand during the next few years.
For instance, as per the Centers for Disease Control and Prevention (CDC), about 1 in 25 hospital patients has at least one healthcare-associated infection every year. Similarly, as per European Centre for Disease Prevention and Control, in 2015, 11,788 (around 8.0%) patients admitted in Intensive Care Unit (ICU) for more than two days suffered from at least one ICU-acquired HAI.
These patients suffered from various HAIs, such as pneumonia, bloodstream infection, and Urinary Tract Infection (UTI). As per the CDC, in U.S. on any given day, about 1 in 31 hospital patients suffer from at least one HAI. Similarly, the World Health Organization (WHO) reported that at any given point of time, of every 100 hospitalized patients, 10 in developing countries and 7 in developed countries acquire at least one HAI.
Such huge number of patients suffering from HAIs requires effective treatment techniques to prevent further complications. Cold plasma demonstrates antimicrobial, antiviral, antifungal properties and helps eliminate HAIs. It is also used for sanitization owing to its properties of killing various types of bacteria.
On the basis of products, the market has been segmented into atmospheric and low-pressure cold plasma. The atmospheric cold plasma accounted for the largest market share in the past and is also expected to witness the fastest growth over the forecast period. Cold Atmospheric Plasma (CAP) is an innovative medical technology with a wide range of applications in healthcare sector, such as infection control, wound healing, and burn treatment. It also has applications in various surgical and non-surgical procedures.
The key market players are using this technology to develop treatment for cancerous cells. All these factors are expected to spur the growth of this segment over the years to come. The market will witness a significant growth owing to various technological advancements along with rising demand for better healthcare treatments and awareness about hygiene. Due to growing application scope in various medical procedures, both the segments are anticipated to witness significant growth over the forecast period.
Wound healing segment held the largest market share in 2017. The ability of cold plasma to kill bacteria, including the drug-resistant bacteria, to prevent further infection, helps in treating chronic wounds. It accelerates the wound healing process and eliminates further complications and related discomforts. Although, many other treatment procedures are present for wound healing, cold plasma treatment is anticipated to be one of the effective ways. This is anticipated to drive the segment further.
Cancer treatment is expected to witness the fastest growth over the forecast period. One of the major breakthroughs in the cold plasma technology is its application in cancer treatment. It has shown efficacy in the pre-clinical model of various cancers, such as skin, brain, lung, breast, bladder, head, and neck cancer. In-vitro and in-vivo studies reveal that cold plasma effectively kills cancer cells. It decreases the velocity of cell migration, which has important implication in the disease treatment.
North America accounted for the largest share of the cold plasma market in 2017 owing to the presence of key industry participants and availability of various FDA-approved products. Moreover, quick adoption of technological advanced products in the regional healthcare industry will fuel the market growth. Rising cases of cancer is also expected to drive the market in this region. For instance, in U.S., approximately 609,640 deaths were caused by cancer in 2018. Such high number fatality cases can be reduced with the help of cold plasma in cancer treatment, thus, driving the growth of the market. Europe is also anticipated to command a significant market share during the forecast period.
This growth can be attributed to a rise in demand for advanced procedures for various treatments, increasing HAI cases, and rising awareness about applications of cold plasma in medicine. Asian countries are estimated to witness the highest growth due to increased penetration of sophisticated treatment procedures for various diseases along with rising disposable income and target population base.In addition, rapidly expanding medical tourism industry, due to better healthcare at lower prices, in APAC region is further projected to boost the product demand. For instance, as per the report on Export Health Services by the Directorate-General of Commercial Intelligence and Statistics of India, in 2015 - 2016, India had 58,300 tourists on medical visas.
Prominent key companies in the market areU.S. Medical Innovations (USMI), LLC, Bovie Medical Corporation, Neoplas Tools GmbH, Europlasma N.V., and P2i Limited. Most of these market players have undertaken strategic initiatives, such as partnership and product launch, to sustain the competition. For instance, in September 2017, USMI and George Washington University entered into a USD 5.3 million agreement to launch new plasma-based cancer therapy program. Such initiatives are anticipated to encourage technological advancements in the field.
Report Attribute |
Details |
Market size value in 2020 |
USD 84.4 million |
Revenue forecast in 2026 |
USD 198.5 million |
Growth Rate |
CAGR of 15.2% from 2018 to 2026 |
Base year for estimation |
2017 |
Historical data |
2014 - 2016 |
Forecast period |
2018 - 2026 |
Quantitative units |
Revenue in USD million and CAGR from 2018 to 2026 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments covered |
Pressure, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U. S. ; Canada; Germany; U. K. ; Japan; China; Brazil; Mexico; South Africa |
Key companies profiled |
U.S. Medical Innovations (USMI), LLC; Bovie Medical Corporation; Neoplas Tools GmbH; Europlasma N.V.; P2i Limited |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global cold plasma market report on the basis of pressure, application, and region:
Pressure Outlook (Revenue USD Million, 2014 - 2026)
Low-Pressure
Atmospheric Pressure
Application Outlook (Revenue USD Million, 2014 - 2026)
Wound Healing
Blood Coagulation
Dentistry
Cancer Treatment
Other Medical Applications
Regional Outlook (Revenue USD Million, 2014 - 2026)
North America
U.S.
Canada
Europe
U.K.
Germany
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
Middle East and Africa
South Africa
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.